# Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide Adjunct

> **NCT05677282** · PHASE4 · RECRUITING · sponsor: **Henry M. Jackson Foundation for the Advancement of Military Medicine** · enrollment: 150 (estimated)

## Conditions studied

- Diarrhoea;Acute
- Diarrhea Travelers

## Interventions

- **DRUG:** Rifaximin 550 MG
- **DRUG:** Azithromycin 500 MG
- **DRUG:** Loperamide

## Key facts

- **NCT ID:** NCT05677282
- **Lead sponsor:** Henry M. Jackson Foundation for the Advancement of Military Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-28
- **Primary completion:** 2025-09
- **Final completion:** 2025-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-05-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05677282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05677282, "Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide Adjunct". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05677282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*